The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Open accessAbstract
Pemigatinib, a selective FGFR1–3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase II study in patients with cholangiocarcinoma harboring FGFR2 fusions/rearrangements, and has gained regulatory approval in the United States. Eligibility for FIGHT-202 was assessed using genomic profiling; here, these data were utilized to characterize the genomic landscape of cholangiocarcinoma and to uncover unique molecular features of patients harboring FGFR2 rearrangements. The results highlight the high percentage of patients with cholangiocarcinoma harboring potentially actionable genomic alterations and the diversity in gene partners that rearrange with FGFR2. Clinicogenomic analysis of pemigatinib-treated patients identified mechanisms of primary and acquired resistance. Genomic subsets of patients with other potentially actionable FGF/FGFR alterations were also identified. Our study provides a framework for molecularly guided clinical trials and underscores the importance of genomic profiling to enable a deeper understanding of the molecular basis for response and nonresponse to targeted therapy. Significance: We utilized genomic profiling data from FIGHT-202 to gain insights into the genomic landscape of cholangiocarcinoma, to understand the molecular diversity of patients with FGFR2 fusions or rearrangements, and to interrogate the clinicogenomics of patients treated with pemigatinib. Our study highlights the utility of genomic profiling in clinical trials. This article is highlighted in the In This Issue feature, p. 211
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 1×
“), which uses hybrid capture–based DNA target enrichment to identify somatic GAs in the coding regions of 315 cancer-related genes and introns from 28 genes often rearranged in cancer (12).”
BackgroundReceptor Specificity of the Fibroblast Growth Factor Family
Ornitz, D. M., Xu, J., Colvin, J. S., McEwen, D. G., MacArthur, C. A., Coulier, F., Gao, G., & Goldfarb, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.15292 · Cited by 1,871
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Self-citationAbou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., Paulson, A. S., Borad, M. J., Gallinson, D., Murphy, A. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30109-1 · Cited by 1,611
Self-citationFrequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E., Fleming, M., Rezazadeh, A., Mellado, B., Varlamov, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817323 · Cited by 1,360
Receptor Specificity of the Fibroblast Growth Factor Family
Zhang, X., Ibrahimi, O. A., Olsen, S. K., Umemori, H., Mohammadi, M., & Ornitz, D. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601252200 · Cited by 1,164
Kouhara, H., Hadari, Y. R., Spivak-Kroizman, T., Schilling, J., Bar-Sagi, D., Lax, I., & Schlessinger, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80252-4 · Cited by 873
Advances and challenges in targeting FGFR signalling in cancer
Babina, I. S., & Turner, N. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.8 · Cited by 799
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update
Khan, S. A., Davidson, B. R., Goldin, R. D., Heaton, N., Karani, J., Pereira, S. P., Rosenberg, W. M. C., Tait, P., Taylor-Robinson, S. D., Thillainayagam, A. V., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301748 · Cited by 797
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Saha, S. K., Zhu, A. X., Fuchs, C. S., & Brooks, G. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0446 · Cited by 786
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 744
Bott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
Bertuccio, P., Malvezzi, M., Carioli, G., Hashim, D., Boffetta, P., El-Serag, H. B., La Vecchia, C., & Negri, E. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.013 · Cited by 648
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M.-C., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.033 · Cited by 610
Lowery, M. A., Ptashkin, R., Jordan, E., Berger, M. F., Zehir, A., Capanu, M., Kemeny, N. E., O'Reilly, E. M., El-Dika, I., Jarnagin, W. R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0078 · Cited by 582
Arai, Y., Totoki, Y., Hosoda, F., Shirota, T., Hama, N., Nakamura, H., Ojima, H., Furuta, K., Shimada, K., Okusaka, T., et al. (2014) · Hepatology · doi:10.1002/hep.26890 · Cited by 553
Goyal, L., Saha, S. K., Liu, L. Y., Siravegna, G., Leshchiner, I., Ahronian, L. G., Lennerz, J. K., Vu, P., Deshpande, V., Kambadakone, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1000 · Cited by 552
Parikh, A. R., Leshchiner, I., Elagina, L., Goyal, L., Levovitz, C., Siravegna, G., Livitz, D., Rhrissorrakrai, K., Martin, E. E., Van Seventer, E. E., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0561-9 · Cited by 518
Ross, J. S., Wang, K., Gay, L., Al-Rohil, R., Rand, J. V., Jones, D. M., Lee, H. J., Sheehan, C. E., Otto, G. A., Palmer, G., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0352 · Cited by 454
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Churi, C. R., Shroff, R., Wang, Y., Rashid, A., Kang, H. C., Weatherly, J., Zuo, M., Zinner, R., Hong, D., Meric-Bernstam, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115383 · Cited by 450
Biliary cancer: Utility of next‐generation sequencing for clinical management
Javle, M., Bekaii‐Saab, T., Jain, A., Wang, Y., Kelley, R. K., Wang, K., Kang, H. C., Catenacci, D., Ali, S., Krishnan, S., et al. (2016) · Cancer · doi:10.1002/cncr.30254 · Cited by 418
Genomic basis for RNA alterations in cancer
PCAWG Transcriptome Core Group, Calabrese, C., Davidson, N. R., Demircioğlu, D., Fonseca, N. A., He, Y., Kahles, A., Lehmann, K.-V., Liu, F., Shiraishi, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-1970-0 · Cited by 393
Goyal, L., Shi, L., Liu, L. Y., Fece de la Cruz, F., Lennerz, J. K., Raghavan, S., Leschiner, I., Elagina, L., Siravegna, G., Ng, R. W. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0182 · Cited by 376
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Dienstmann, R., Rodon, J., Prat, A., Perez-Garcia, J., Adamo, B., Felip, E., Cortes, J., Iafrate, A. J., Nuciforo, P., & Tabernero, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt419 · Cited by 365
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
Graham, R. P., Barr Fritcher, E. G., Pestova, E., Schulz, J., Sitailo, L. A., Vasmatzis, G., Murphy, S. J., McWilliams, R. R., Hart, S. N., Halling, K. C., et al. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.03.014 · Cited by 313
Activating FGFR2–RAS–BRAF Mutations in Ameloblastoma
Brown, N. A., Rolland, D., McHugh, J. B., Weigelin, H. C., Zhao, L., Lim, M. S., Elenitoba-Johnson, K. S. J., & Betz, B. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1069 · Cited by 298
A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases
Chen, H., Ma, J., Li, W., Eliseenkova, A. V., Xu, C., Neubert, T. A., Miller, W. T., & Mohammadi, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.028 · Cited by 291
Fabrizio, D. A., George Jr, T. J., Dunne, R. F., Frampton, G., Sun, J., Gowen, K., Kennedy, M., Greenbowe, J., Schrock, A. B., Hezel, A. F., et al. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.05.06 · Cited by 260
Hakimi, A. A., Chen, Y.-B., Wren, J., Gonen, M., Abdel-Wahab, O., Heguy, A., Liu, H., Takeda, S., Tickoo, S. K., Reuter, V. E., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.09.005 · Cited by 231
Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., Falk, S., Gillmore, R., Wadsley, J., Patel, K., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4003 · Cited by 220
Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype
Jain, A., Borad, M. J., Kelley, R. K., Wang, Y., Abdel-Wahab, R., Meric-Bernstam, F., Baggerly, K. A., Kaseb, A. O., Al-shamsi, H. O., Ahn, D. H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00080 · Cited by 173
Liu, P. C. C., Koblish, H., Wu, L., Bowman, K., Diamond, S., DiMatteo, D., Zhang, Y., Hansbury, M., Rupar, M., Wen, X., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0231877 · Cited by 158
Self-citationCancer review: Cholangiocarcinoma
Blechacz, B. R. A., Ghouri, Y. A., & Mian, I. (2015) · Journal of Carcinogenesis · doi:10.4103/1477-3163.151940 · Cited by 154
Krook, M. A., Lenyo, A. M., Wilberding, M., Barker, H. D., Dantuono, M., Bailey, K. M., Chen, H., Reeser, J. W., Wing, M. R., Miya, J., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0631 · Cited by 148
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Milman, T. (2011) · Yearbook of Ophthalmology · doi:10.1016/j.yoph.2011.03.038 · Cited by 127
Recurrence after surgical resection of intrahepatic cholangiocarcinoma
Yamamoto, M., Takasaki, K., Otsubo, T., Katsuragawa, H., & Katagiri, S. (2001) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s005340170039 · Cited by 123
Molecular profiling of biliary tract cancer: a target rich disease
Jain, A., & Javle, M. M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.09.01 · Cited by 106
Mukkamalla, S. K. R., Naseri, H. M., Kim, B. M., Katz, S. C., & Armenio, V. A. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7056 · Cited by 103
Krook, M. A., Bonneville, R., Chen, H., Reeser, J. W., Wing, M. R., Patacsil, D., Smith, A. M., Dao, T., Samorodnitsky, E., Paruchuri, A., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a004002 · Cited by 90
Cha, J. Y., Maddileti, S., Mitin, N., Harden, T. K., & Der, C. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803998200 · Cited by 87
Itoh, H., Hattori, Y., Sakamoto, H., Ishii, H., Kishi, T., Sasaki, H., Yoshida, T., Koono, M., Sugimura, T., & Terada, M. (1994) · PubMed · Cited by 78
Lowery, M. A., Goff, L. W., Keenan, B. P., Jordan, E., Wang, R., Bocobo, A. G., Chou, J. F., O'Reilly, E. M., Harding, J. J., Kemeny, N. E., et al. (2019) · Cancer · doi:10.1002/cncr.32463 · Cited by 70
Structural Mimicry of A-Loop Tyrosine Phosphorylation by a Pathogenic FGF Receptor 3 Mutation
Huang, Z., Chen, H., Blais, S. P., Neubert, T. A., Li, X., & Mohammadi, M. (2013) · Structure · doi:10.1016/j.str.2013.07.017 · Cited by 49
The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?
Ilyas, S. I., & Borad, M. J. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.08.12 · Cited by 40
Cited by
Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Goyal, L., Meric-Bernstam, F., Hollebecque, A., Valle, J. W., Morizane, C., Karasic, T. B., Abrams, T. A., Furuse, J., Kelley, R. K., Cassier, P. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2206834 · Cited by 613
Self-citationEASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
Alvaro, D., Gores, G. J., Walicki, J., Hassan, C., Sapisochin, G., Komuta, M., Forner, A., Valle, J. W., Laghi, A., Ilyas, S. I., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.010 · Cited by 344
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
Roskoski, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105463 · Cited by 335
Meric-Bernstam, F., Bahleda, R., Hierro, C., Sanson, M., Bridgewater, J., Arkenau, H.-T., Tran, B., Kelley, R. K., Park, J. O., Javle, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0697 · Cited by 258
Wu, Q., Zhen, Y., Shi, L., Vu, P., Greninger, P., Adil, R., Merritt, J., Egan, R., Wu, M.-J., Yin, X., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1168 · Cited by 104
Metadata
- Authors
- Silverman, I. M., Hollebecque, A., Friboulet, L., Owens, S., Newton, R. C., Zhen, H., Féliz, L., Zecchetto, C., Melisi, D., & Burn, T. C.
- Venue
- Cancer Discovery
- Published
- 2021-02-01
- Volume
- 11
- Issue
- 2
- Pages
- 326-339
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3103246749
- Cited by
- 283
- References
- 48
- FWCI
- 28.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.